FOLH1 and posterior cortical atrophy: With this in mind, many of the clinical trials of new therapies for advanced PCa that are currently recruiting or recently completed use immunotherapeutic approaches (Table 1), with some targeting specific antigens such as prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), PAP, NY-ESO-1, MAGE-C2, Mucin 1, and Bcl-xl (the latter in combination with the CAF®09b adjuvant).